Evidence map›Paper›PMID 23735753›Full record

ArticleNeuroscience2013

Kinin-B2 receptor exerted neuroprotection after diisopropylfluorophosphate-induced neuronal damage.

W Torres-Rivera, D Pérez, K-Y Park, M Carrasco, M O Platt, V A Eterović, P A Ferchmin, H Ulrich, A H Martins

Open access · greenAbstract read
In one paragraph

Article in Neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Mastoparan M extracted fromIranian journal of basic medical sciences · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Bradykinin-mediated CaJournal of cellular and molecular medicine · 2018
    Article
  6. Article
  7. Involvement of bradykinin in brain edema development after ischemic stroke.Pflugers Archiv : European journal of physiology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

W Torres-RiveraDepartment of Biochemistry, Universidad Central del Caribe, Bayamón, PR 00956, USA.
D Pérez
K-Y Park
M Carrasco
M O Platt
V A Eterović
P A Ferchmin
H Ulrich
A H Martins
Central University of the Caribbean · PRGeorgia Institute of Technology · USThe Wallace H. Coulter Department of Biomedical Engineering · USUniversidade de São Paulo · BR

Funding

VIRUS E34 TAILSPIKE: MODULE FOR PROTEIN:LPS INTERACTIONP20RR016470 · NCRR · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI ORTIZ-ZUAZAGA, ELENA M · 2001 to 2011
$31.2M
Thyroid hormones and synaptic functionU54NS039408 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI BYKHOVSKAIA, MARIA · 1999 to 2012
$14.0M
Regulation of synaptic vesicle mobilization,priming and recycling by complexinU54NS083924 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI BYKHOVSKAIA, MARIA · 2013 to 2015
$4.3M
PROTECTION AGAINST ORGANOPHOSPHATE NEUROTOXINS BY TOBACCO CEMBRANOIDSU01NS063555 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI FERCHMIN, P. A. · 2008 to 2010
$2.0M
NCRR NIH HHS P20 RR016470NCRR NIH HHS P20RR016470-AABRENINDS NIH HHS SNRP U54NS039408-10NINDS NIH HHS U01 NS063555NINDS NIH HHS U54 NS039408NINDS NIH HHS U54 NS083924NINDS NIH HHS UO1NS063555
6 · The paper itself

Abstract

The kinin-B2 receptor (B2BKR) activated by its endogenous ligand bradykinin participates in various metabolic processes including the control of arterial pressure and inflammation. Recently, functions for this receptor in brain development and protection against glutamate-provoked excitotoxicity have been proposed. Here, we report neuroprotective properties for bradykinin against organophosphate poisoning using acute hippocampal slices as an in vitro model. Following slice perfusion for 10min with diisopropylfluorophosphate (DFP) to initiate the noxious stimulus, responses of pyramidal neurons upon an electric impulse were reduced to less than 30% of control amplitudes. Effects on synaptic-elicited population spikes were reverted when preparations had been exposed to bradykinin 30min after challenging with DFP. Accordingly, bradykinin-induced population spike recovery was abolished by HOE-140, a B2BKR antagonist. However, the kinin-B1 receptor (B1BKR) agonist Lys-des-Arg(9)-bradykinin, inducing the phosphorylation of mitogen-activated protein kinase (MEK/MAPK) and cell death, abolished bradykinin-mediated neuroprotection, an effect, which was reverted by the ERK inhibitor PD98059. In agreement with pivotal B1BKR functions in this process, antagonism of endogenous B1BKR activity alone was enough for restoring population spike activity. On the other hand pralidoxime, an oxime, reactivating acetylcholinesterase (AChE) after organophosphate poisoning, induced population spike recovery after DFP exposure in the presence of bradykinin and Lys-des-Arg(9)-bradykinin. Lys-des-Arg(9)-bradykinin did not revert protection exerted by pralidoxime, however when instead bradykinin and Ly-des-Arg(9)-bradykinin were superfused together, recovery of population spikes diminished. These findings again confirm the neuroprotective feature of bradykinin, which is, diminished by its endogenous metabolites, stimulating the B1BKR, providing a novel understanding of the physiological roles of these receptors.

Indexed as

Action PotentialsAnimalsBradykininBradykinin B2 Receptor AntagonistsHippocampusIsoflurophateMaleNeuronsNeuroprotective AgentsOrgan Culture TechniquesRats, Sprague-DawleyReceptor, Bradykinin B2BradykininBradykinin B2 Receptor AntagonistsicatibantIsoflurophateNeuroprotective AgentsReceptor, Bradykinin B22-PAMacetylcholinesteraseAChEACSFartificial cerebrospinal fluidB1BKRB2BKRBKbradykininDFPdiisopropylfluorophosphatekinin-B1 receptorkinin-B2 receptorMEK/MAPKmitogen-activated protein kinaseneuroprotectionNMDAN-methyl-d-aspartateOPsorganophosphateorganophosphatesphosphatidylinositol kinasePI3Kpopulation spikepralidoximePS

Identifiers

PMID23735753
PMCPMC3740336
OpenAlexW2019431838

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.